![Ruti-Alon_150x200-1[1]](https://kenes-exhibitions.com/biomed/wp-content/uploads/elementor/thumbs/Ruti-Alon_150x200-11-pxsgcipwuxa3vzcw5ps3gu4pkhl01q3pabyr93tq0w.jpg "Ruti-Alon_150x200-1[1]")
![Ora-Dar_150x200-1[1]](https://kenes-exhibitions.com/biomed/wp-content/uploads/elementor/thumbs/Ora-Dar_150x200-11-pxsgxl9o284i5ar24bo0v0poyfq7lgr36mfljel0jk.jpg "Ora-Dar_150x200-1[1]")
![Nissim-Darvish_150x200-1[1]](https://kenes-exhibitions.com/biomed/wp-content/uploads/elementor/thumbs/Nissim-Darvish_150x200-11-pxsh1381i0wxd1o3ou4154xgk2he8wn4bxunuhe9ds.jpg "Nissim-Darvish_150x200-1[1]")
Conference Moderators
Abraham Accords Healthcare Collaboration and Innovation
Susan K. Finston, JD/MPP
Senior Advisor, President
Princeton Capital Advisors, Finston Consulting LLC
Are recent trends reshuffling MedTech companies value capture towards data, digital and commercialization elements?
Arjun (JJ) Desai, MD
CSIO
INSIGHTEC
Read More
Are recent trends reshuffling MedTech companies value capture towards data, digital and commercialization elements?
Gilad Glick, MBA
VP JJDC MedTech, Growth Stage Executive
Johnson & Johnson Innovation Fund
AI Tapestry: Optimizing the Interaction of AI and Biopharma
Anat Naschitz, PhD
CEO
9xchange
How Do We Make Academic Translation Medicine replicable and relevant?
Aviv Shoher, MBA, LLB
Managing Partner,
IMed Capital
Ophthalmology, from R&D to Commercialization
Prof. Anat Loewenstein, MD
Director, Ophthalmology Division Sidney Fox Chair in Ophthalmology
Sackler Faculty of Medicine, Tel Aviv University President, Israeli Ophthalmological Society
High Pace Innovation in Dermatology & Medical Aesthetics
Shy Zyman, MBA
Partner, LifeScience
Cukierman & Co. Life Sciences
High Pace Innovation in Dermatology & Medical Aesthetics
Laurent Choppe, PhD, MBA
Managing Partner
Cukierman & Co. Life Sciences
Navigating Global Collaborations in Times of Uncertainty: Can we turn challenges into growth opportunities?
Daphna Murwitz, LLB
Co-Founder & CEO
8400 Health Network
Read More
Can we Successfully Diagnose and Guide Patient’s Optimal Cancer Treatment?
Prof. Nir Friedman, PhD
Prof. Computer Science & Medicine
Hebrew University
Bio Convergence - Everything That Rises Must Converge
Nathalie Bloch, MD MPA
Senior Advisor
Israel Innovation Authority
Facts and Myths on Ex-Liver Delivery of Nucleic Acid Therapeutics and New Horizons to Cure Rare Disorders
Yael Gruenbaum-Cohen, PhD
Venture Partner
aMoon Velocity
Facts and Myths on Ex-Liver Delivery of Nucleic Acid Therapeutics and New Horizons to Cure Rare Disorders
Iris Grossman, PhD
CThO
Eleven Therapeutics
Let Food be Thy Medicine and Medicine be Thy Food
![Tammy-Meiron_450x600[1]](https://kenes-exhibitions.com/biomed/wp-content/uploads/elementor/thumbs/Tammy-Meiron_450x6001-pxst0qnvz3t8yio75f4c67lt62xh129mcextoxds00.jpg "Tammy-Meiron_450x600[1]")
Tammy Meiron, PhD
CTO
Fresh Start FoodTech Incubator
Robots Dancing with Humans in the Healthcare Systems and Homes
Dvir Cohen
CEO & President
Momentis Surgical
Patients are Consumers at Home – How Far Can They Manage Their Health?
Prof. Varda Shalev, MD, MPA
Managing Partner
Team8 Health
AI tapestry: Optimizing the Interaction of AI and Biopharma
Yair Benita, PhD
CTO
Aion Labs
Can we Successfully Diagnose and Guide Patients’ Optimal Cancer Treatment?
Ofer Sharon, MD
CEO
OncoHost
Are Cancer Therapeutics Fulfilling the Promise?
Yaron Daniely, PhD MBA
Partner & Head
aMoon Alpha
Do we Know Enough About the Brain to Treat Neurological Disorders?
Barry Greene
CEO
Sage Therapeutics
US Launch Preparation: The Essential Factors for Optimal Reimbursement & Maximum Profitability
Pete Vaccaro, MA
Partner
Formulary Insights
Read More
US Launch Preparation: The Essential Factors for Optimal Reimbursement & Maximum Profitability
Amy Heath, BA, MSM
Partner
Formulary Insights